EVALUATION OF SERUM FERRITIN AS AN INFLAMMATORY BIOMARKER IN ACUTE CORONARY SYNDROME PATIENTS: A CASE-CONTROL STUDY

Abstract

Context/Background: Acute Coronary Syndrome is still one of the most common
and deadly cardiovascular emergencies worldwide.. Serum ferritin, an acute-phase
reactant, has been increasingly studied as a biomarker of oxidative stress and
systemic inflammation in cardiovascular diseases.
Aims/Objectives: To determine serum ferritin concentrations in ACS patients and
evaluate their correlation with conventional risk factors for cardiovascular disease.
Methodology: A hospital-based, case-control study was conducted including 50 ACS
patients and 50 age- and sex-matched healthy controls. Serum ferritin was measured
by ELISA. Fasting blood glucose, postprandial blood glucose, lipid profile, CK-MB,
and BMI were also assessed. Statistical analysis included t-tests and Pearson
correlation.
Results: Serum ferritin concentrations were considerably higher in the ACS group
(357.56 ± 185.15 ng/mL) than in the control group (107.68 ± 55.87 ng/mL), showing
a highly significant difference (p < 0.001).Ferritin showed a strong positive
correlation with fasting (r = 0.757, p = 0.01) and postprandial blood sugar (r = 0.724,
p = 0.01), but no significant correlation with lipid parameters or blood pressure.
Conclusions: Serum ferritin is significantly elevated in ACS and correlates
positively with glycemic status. It may serve as an early, inexpensive, and accessible
biomarker for inflammation and cardiovascular risk stratification.